US Patent

US11603356 — Amorphous form of a complement component C5a receptor

Method of Use · Assigned to Chemocentryx Inc · Expires 2039-11-27 · 14y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects an amorphous form of a complement component 5a receptor, as well as pharmaceutical compositions and methods of treatment using it.

USPTO Abstract

Provided herein is an amorphous form of a complement component 5a receptor having the formula of Compound 1Also provided herein are pharmaceutical compositions and methods of treatment using the amorphous form of Compound 1, described herein.

Drugs covered by this patent

Tavneos (AVACOPAN) · Chemocentryx

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3558`	—	Tavneos

Patent Metadata

Patent number: US11603356
Jurisdiction: US
Classification: Method of Use
Expires: 2039-11-27
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Chemocentryx Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.